Biomea Fusion, Inc. (BMEA)

NASDAQ: BMEA · IEX Real-Time Price · USD
9.03 0.75 (9.06%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap262.27M
Revenue (ttm)n/a
Net Income (ttm)-30.36M
Shares Out29.04M
EPS (ttm)-1.54
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume209,089
Open8.25
Previous Close8.28
Day's Range8.25 - 9.44
52-Week Range7.00 - 22.22
Betan/a
AnalystsBuy
Price Target22.60 (+150.3%)
Earnings DateNov 10, 2021

About BMEA

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is headquartered in Redwood City, California.

IndustryBiotechnology
IPO DateApr 16, 2021
Employees47
Stock ExchangeNASDAQ
Ticker SymbolBMEA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for Biomea Fusion stock is "Buy." The 12-month stock price forecast is 22.60, which is an increase of 150.28% from the latest price.

Price Target
$22.60
(150.28% upside)
Analyst Consensus: Buy

News

Biomea Fusion Announces Participation at the H.C. Wainwright 2022 BioConnect Conference

REDWOOD CITY, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irre...

4 days ago - GlobeNewsWire

Biomea Fusion Announces 2022 Clinical Development Plan to Initiate Studies in up to Seven Different Tumor Types and i...

REDWOOD CITY, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irre...

5 days ago - GlobeNewsWire

Biomea Fusion Moves into New Headquarters and Expands R&D Facility

REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irre...

1 week ago - GlobeNewsWire

Biomea Fusion to be added to NASDAQ Biotechnology Index

REDWOOD CITY, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irre...

1 month ago - GlobeNewsWire

Biomea Fusion to Participate in Two Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irre...

2 months ago - GlobeNewsWire

Biomea Fusion Publishes Abstract on BMF-219 at ASH Annual Meeting

REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irre...

2 months ago - GlobeNewsWire

Biomea Fusion Reports Third Quarter 2021 Financial Results and Business Highlights

REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel smal...

2 months ago - GlobeNewsWire

The Moonshot Investor: The Insider Track Strategy

Excerpts of this article were originally published on October 4 and 18, 2021, as part of Tom Yeung's Moonshot Investor series. Investors interested in finding stocks with 100x potential or more can subs...

Other symbols:GLSIVOLT
3 months ago - InvestorPlace

3 Stocks Insiders Are Snapping Up. Do They Know Something We Don't?

Insider trading is heavily regulated, but it still happens, and it's worth paying attention to big moves from insiders for potential profits. The post 3 Stocks Insiders Are Snapping Up.

Other symbols:VOLT
3 months ago - InvestorPlace

Biomea Fusion To Start Early-Stage Leukemia Setting Trial With BMF-219

The FDA has signed off Biomea Fusion Inc's (NASDAQ: BMEA) Investigational New Drug application to begin a Phase 1 trial of BMF-219, a selective irreversible menin inhibitor. The trial will include adult...

3 months ago - Benzinga

Biomea Fusion Announces FDA Clearance of Investigational New Drug Application for Irreversible Menin Inhibitor BMF-219

REDWOOD CITY, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a biopharmaceutical company focused on the discovery and development of irreversible small molecul...

3 months ago - GlobeNewsWire

Biomea Fusion Reports Second Quarter 2021 Financial Results and Business Highlights

REDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversi...

5 months ago - GlobeNewsWire

BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer

REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversi...

6 months ago - GlobeNewsWire

Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights

-- Received $167 million in aggregate gross proceeds in  April from initial public offering -- – Advancing lead oncology program BMF-219, a small molecule irreversible menin inhibitor, toward IND filing...

7 months ago - GlobeNewsWire

2 Hot Biotech IPOs to Consider

These companies are already making great strides where few dare to tread.

Other symbols:RXRX
8 months ago - The Motley Fool

Biomea Announces Closing of Initial Public Offering

REDWOOD CITY, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery, development and commercial...

8 months ago - GlobeNewsWire

Biomea Fusion stock opens 18% above IPO price

Biomea Fusion Inc. rallied out of the gate Friday, as shares of the California-based biopharmaceutical company focused on treatment of genetically defined cancers opened 17.6% above the initial public o...

8 months ago - Market Watch

Biomea Announces Pricing of Initial Public Offering

REDWOOD CITY, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery, development and commercial...

9 months ago - GlobeNewsWire